Literature DB >> 19535956

Therapeutic hypothermia for acute liver failure.

R Todd Stravitz1, Fin Stolze Larsen.   

Abstract

Cerebral edema is a potentially life-threatening complication of acute liver failure, the syndrome of abrupt loss of liver function in a patient with a previously healthy liver. Although the prevalence of cerebral edema appears to be decreasing, patients with rapidly progressive (hyperacute) liver failure, such as after acetaminophen overdose, remain at highest risk. In severe cases of cerebral edema, intracranial hypertension develops and leads to brain death after brainstem herniation or to anoxic brain injury and permanent neurologic impairment. Intracranial hypertension in patients with acute liver failure often can be temporarily controlled by manipulating body position, increasing the degree of sedation, and increasing blood osmolarity through pharmacologic means. However, these maneuvers often postpone, but do not eliminate, the risk of brainstem herniation unless orthotopic liver transplantation or spontaneous liver regeneration follows in short order. To buy time, the induction of therapeutic hypothermia (core temperature 32 degrees C-35 degrees C) has been shown to effectively bridge patients to transplant. Similar to the experience in patients with cerebral edema after other neurologic insults, hypothermia reduces cerebral edema and intracranial hypertension in patients with acute liver failure by decreasing splanchnic ammonia production, restoring normal regulation of cerebral hemodynamics, and lowering oxidative metabolism within the brain. Hypothermia may also ameliorate the degree of liver injury. Hypothermia has not been adequately studied for its safety and theoretically may increase the risk of infection, cardiac dysrhythmias, and bleeding, all complications independently associated with acute liver failure. Therefore, although an ample body of experimental and human data provides a rationale for the use of therapeutic hypothermia in patients with acute liver failure, multicenter, randomized, controlled clinical trials are needed to confirm that hypothermia secures brain viability and improves survival without causing harm.

Entities:  

Mesh:

Year:  2009        PMID: 19535956     DOI: 10.1097/CCM.0b013e3181aa5fb8

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  31 in total

Review 1.  Management in acute liver failure.

Authors:  Subrat K Acharya
Journal:  J Clin Exp Hepatol       Date:  2014-12-03

2.  Favorable long-term outcome following severe neonatal hyperammonemic coma in a patient with argininosuccinate synthetase deficiency.

Authors:  Isabelle De Bie; Emmanuelle Lemyre; Marie Lambert
Journal:  JIMD Rep       Date:  2011-06-22

3.  Hepatobiliary Quiz (Answers)-14 (2015).

Authors:  Sahaj Rathi; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2015-06-27

4.  Complications of Acute Liver Failure.

Authors:  Santiago J Munoz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-10

Review 5.  Neurological management of fulminant hepatic failure.

Authors:  Jennifer A Frontera; Thomas Kalb
Journal:  Neurocrit Care       Date:  2011-04       Impact factor: 3.210

6.  Antibiotics in Acute Liver Failure (ALF).

Authors: 
Journal:  J Clin Exp Hepatol       Date:  2015-02-10

Review 7.  Glutamine as a mediator of ammonia neurotoxicity: A critical appraisal.

Authors:  Jan Albrecht; Magdalena Zielińska; Michael D Norenberg
Journal:  Biochem Pharmacol       Date:  2010-07-21       Impact factor: 5.858

8.  Management of hepatic encephalopathy.

Authors:  Jennifer A Frontera
Journal:  Curr Treat Options Neurol       Date:  2014-06       Impact factor: 3.598

Review 9.  Role of inflammation and infection in the pathogenesis of human acute liver failure: Clinical implications for monitoring and therapy.

Authors:  Mhairi C Donnelly; Peter C Hayes; Kenneth J Simpson
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

Review 10.  Management of acute liver failure.

Authors:  R Todd Stravitz; David J Kramer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-08-04       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.